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Abstract 
This thesis set out to examine whether the demographic diversity of participants in clinical trials 
involving allogeneic stem cell transplant recipients matched the diversity of the actual allogeneic 
recipient population overall. It is important that clinical trials study new therapies in a population 
that represents characteristics of the overall treatment population in order to gain accurate safety 
and efficacy data. The actual diversity of the allogeneic transplant population was determined 
using data reported to the Center for International Blood & Marrow Transplant Research 
(CIBMTR) registry. Then, a comprehensive literature review was conducted to identify the 
population of allogeneic transplant recipients who took part in clinical research. In comparing the 
two populations, it was determined that women are well-represented in allogeneic transplant 
trials, while non-white minorities remain underrepresented. These findings demonstrate that 
there is more work be done in order to ensure everyone has equal access to clinical trials.  
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Introduction and Background 
Hematopoietic stem cell transplantation (HSCT) is a widely recognized therapeutic 
option for treating a variety of hematologic malignancies and immunologic deficiencies. With 
more aggressive disorders, HSCT remains the only potentially curative option after exhausting 
chemotherapeutic treatments. There are two types of hematopoietic transplants: autologous and 
allogeneic. Simply defined, autologous HSCT involves removing the patient’s stem cells once 
they achieve remission, giving the patient more chemotherapy, and subsequently re-infusing the 
stem cells in order to recover bone marrow function (NMDP, n.d.). Allogeneic transplants follow 
a similar path; however, they differ in stem cell source. Instead of stem cells coming from the 
patient’s own system, they come from a healthy volunteer donor (NMDP, n.d.). While 
autologous transplantation remains a highly valued tool for treating patients with these serious 
conditions, this thesis will focus on allogeneic HSCT recipients. 
In order to qualify for an allogeneic transplant, a patient must have a stem cell donor that 
can be considered a match (NMDP, n.d.). Both the patient and donor are tested for certain 
molecular markers found on the surface of most cells in the body. These markers are called 
human leukocyte antigens (HLA; NMDP, n.d.). Because these markers help the body identify 
which cells belong there and which do not, it is essential for donor stem cells to have a high 
degree of HLA match. It is often easier for patients to find matched donors within their own 
families because they share genetic traits (NMDP, n.d.). Without a related donor option, 
however, patients may turn to the National Marrow Donor Program (NMDP) for help. The 
NMDP is a nonprofit organization based in the United States that maintains a registry of 
volunteers who are willing to be donors for patients in need of HSCT.  
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The NMDP’s Be the Match Registry is vital for patients who need allogeneic transplants 
because they instantly have access to HLA information for millions of potential donors. Once the 
patient’s HLA has been tested, a transplant center can quickly search the registry for donors that 
may be considered an HLA match (NMDP, n.d.). According to the NMDP (n.d.), Caucasian 
patients today have a 97% chance of finding a matched donor, yet minorities have a much lower 
likelihood. For instance, African Americans searching for a donor only have a 76% chance of 
finding one (NMDP, n.d.). If a donor cannot be identified from the pool of adult volunteers in the 
Be the Match Registry, the patient may be able to find one from the NMDP’s umbilical cord 
blood registry.  
Stem cells normally exist in the bone marrow or peripheral blood; however, they can also 
be found in the umbilical cord blood of a newborn baby. Before the child is born, the parents 
decide if they want to donate their child’s umbilical cord blood and if so, the cells are collected 
from the cord after the baby is delivered. Once the stem cells are harvested, they undergo HLA 
testing and are cryopreserved in an umbilical cord blood bank. The cord blood registry is much 
smaller than the adult donor registry; therefore, the likelihood of finding a matched donor 
remains low. In fact, while there are approximately 126,000 white cord blood units, there are 
only 16,000 Black/African American cord blood units (H.R.S.A., n.d.). The search for cord 
blood units from American Indians or Pacific Islanders is even worse, with only 370 and 222, 
respectively (H.R.S.A., n.d.). Allogeneic HSCT using umbilical cord blood stem cells often have 
a high degree of HLA mismatch; and typically with more mismatch comes more post-HSCT 
complications for the recipient (Petersdorf et al., 1998). However, cord blood HSCT is somewhat 
unique from other stem cell sources since HLA differences are usually better tolerated for 
reasons that are not completely understood (Eapen et al., 2007).   
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The NMDP is aware of the challenges facing non-white minorities in the donor search 
process and has implemented several programs focused on adding more racially and ethnically 
diverse unrelated donors and cord blood units to its registry (Johansen et al., 2008). While 
increased minority education, recruitment, and funding efforts have dramatically increased the 
odds of finding a matched unrelated donor, there remains an unfulfilled need (Johansen et al., 
2008).  
The NMDP registries are not the only instance where there exists an underrepresentation 
of select groups; it is also a significant problem in the clinical research realm (Murthy et al., 
2004). For most of the twentieth century, the majority of clinical trial participants were white 
males This led to a large gap in access for participation in clinical trials for minorities, women, 
and children (Emanuel et al., 2011). Without their participation, little was known about how 
novel therapies would affect these populations. Because variable therapeutic responses and 
toxicities can be potentially influenced by genetic differences, it is important to study therapies 
in a diverse population.  
Participant diversity is also important from an ethical standpoint because everyone should 
be given equal opportunities to participate in clinical trials whenever possible. This is reflected in 
The Belmont Report issued by the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research in 1978, which called for equal selection of participants to 
share in the burdens and benefits of clinical research (Emanuel et al., 2011). This landmark 
report brought to light ethical concerns in research and led the way to legislation that called for 
greater inclusion of minorities, women, and children in clinical research.  
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Improving the Inclusion of Minorities in Clinical Research 
Recognizing the need to demonstrate the safety and efficacy of new therapies in a wide 
variety of patients, the United States government took action to ensure the inclusion of women, 
children, and minorities in clinical research. As detailed by Emanuel et al. (2011), the U.S. Food 
& Drug Administration (FDA) updated its guidance to allow for the inclusion of women of 
childbearing potential in clinical research in 1993 and issued new guidance stating that the 
overall diversity of research participants “should, in general, reflect the population that will 
receive the drug when it is marketed” (Emanuel et al., 2011). The Women’s Health Equity Act 
was also passed in 1993, calling for “greater equity in the delivery of health care services to 
women through expanded research on women’s health issues, improved access to health care 
services, and the development of disease prevention activities responsive to the needs of women” 
(Emanuel et al., 2011). In accordance with congressional mandate, the FDA then created the 
Office of Women’s Health in 1994.  
Though children had previously been allowed to participate, the real push for the 
inclusion of children in clinical research didn’t begin until 1998. That year, the U.S. National 
Institutes of Health (NIH) urged researchers to include children unless there were scientific or 
ethical reasons to exclude them (Emanuel et al., 2011). The Pediatric Equity Act of 2003 also 
marked a milestone because it required pharmaceutical companies to perform clinical research in 
pediatrics when investigating new drugs and biologic products (Emanuel et al., 2011). 
With regard to HSCT legislature, the Stem Cell Therapeutic and Research Act of 2005 
and the Stem Cell Therapeutic and Research Reauthorization Act of 2010 are two laws that 
helped HSCT research make great strides. As discussed on the website for the Health Resources 
and Services Administration (HRSA), the Stem Cell Acts of 2005 and 2010 are responsible for 
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both the creation of the NMDP and the expansion of the requirements of the registry to increase 
its number of donors and cord blood units (H.R.S.A., n.d.). Also in accordance with these laws, 
all allogeneic HSCT recipients must be registered with the Center for International Blood & 
Marrow Transplant Research (CIBMTR). In doing so, the CIBMTR collects information to track 
outcomes of HSCT recipients in order to large scale outcomes data and practice trends in the 
field that influence clinical research approaches for future transplant candidates. The incredible 
amount of data gathered by the CIBMTR has led to pivotal retrospective analyses that contribute 
to the development of new treatment guidelines for hematologic malignancies and immunologic 
disorders.  
Determining the Study Population 
 Autologous transplants do not require donors as the recipients receive their own cells. 
However, allogeneic transplants are complicated by the need for an HLA-matched donor to 
donate stem cells to the recipient. A large amount of HSCT research is performed in patients 
undergoing allogeneic transplants in order to prevent malignant relapse and help mitigate the 
effects of post-transplant complications. Also, since non-white minorities often face riskier 
transplant courses because they are unlikely to find matched donors, they ideally should be 
included in clinical trials in order to prevent, treat, and alleviate the burden of post-transplant 
complications. With those facts in mind, it was determined that only clinical trials involving 
allogeneic HSCT recipients would be included in the investigation for this thesis. 
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Purpose and Hypothesis 
As previously detailed, much time and effort have been dedicated to ensuring that 
everyone has equal access to clinical research, regardless of gender, race, and age. Though 
clinical research participants were primarily white men just decades ago, there have been 
legislative improvements calling for the inclusion of participants who would not have been 
allowed previously. The primary purpose of this thesis was to examine whether those allogeneic 
transplant recipients who participate in clinical research are representative of the overall 
allogeneic transplant recipient population as a whole. Gender and race were the main focus of the 
investigation while age played a minor role.  
This thesis sought to utilize information contained in the CIBMTR database in order to 
determine demographic characteristics of allogeneic transplant recipients in recent years. Once 
the characteristics of allogeneic HSCT recipients were known, a comprehensive review of 
literature surrounding the results of HSCT clinical trials facilitated the investigation into whether 
the diversity of participants in those trials truly reflected the population of allogeneic transplant 
recipients in the United States.  
The hypothesis of this thesis was that the diversity of the participants enrolled in HSCT 
clinical trials would not accurately represent the makeup of the population of allogeneic 
transplant recipients. By investigating this in detail, this thesis sought to demonstrate whether or 
not more work needs to be done to increase the inclusion of underrepresented minorities into 
clinical trials that may help save lives in the future.  
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Methods 
Prior to beginning the investigation, the formal thesis proposal and study plan were 
submitted to the Eastern Michigan University Institutional Review Board (IRB). Also submitted 
was documentation that included study team training and a formal request to the University 
Human Subjects Review Committee for approval to conduct research involving human subjects. 
This study was concluded to be exempt from IRB oversight due to the minimal risk of harm to 
the humans involved in the study. 
The investigation into the diversity of participants in allogeneic HSCT clinical trials 
required two steps: identification of the participants who were eligible to enroll in the clinical 
trials and determination of the diversity of the actual clinical trial participants.      
Identifying the Potential Clinical Trial Participants 
In order to understand who is participating in allogeneic HSCT clinical trials, the pool of 
eligible subjects had to be identified. The CIBMTR maintains a database of allogeneic 
transplants performed in recent decades and, as the name implies, it is dedicated to improving 
HSCT outcomes through research. In keeping with that goal, the CIBMTR allows investigators 
to submit requests for data from its expansive database. Therefore, a Custom Information 
Request Form was submitted through the CIBMTR webpage for allogeneic transplants 
performed in the United States between January 1, 2010 and December 31, 2014, a total of five 
complete years. The data requested was meant to define the traits of the allogenic HSCT 
recipient population. 
In correspondence with the CIBMTR, however, it was discovered that the analysis of its 
2014 data was not yet complete and it would not release that information at this time. It instead 
provided this researcher with the CIBMTR’s Annual Progress Report for 2013 (CIBMTR, 2013), 
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which included information about the allogeneic transplant population. In addition, the Health 
Resources and Services Administration—an agency of the United States’ Department of Health 
and Human Services—publishes information utilizing CIBMTR data (H.R.S.A., n.d.). It was 
through these two resources that the allogeneic transplant recipient diversity was determined for 
this thesis. In keeping with the proposed plan, five years’ worth of data was used that included 
transplants performed between January 1, 2009 and December 31, 2013.  
Determining the Diversity of Clinical Trial Participants 
After identifying the pool of eligible research participants, a literature review explored 
who among HSCT recipients were actually enrolling in clinical trials. Included in the review of 
recent publications of HSCT research studies were prospective trials with an intervention; any 
retrospective or purely observational studies were discounted. For the purposes of this thesis, an 
intervention was defined as a drug, survey, or other specialty procedure. To be included in this 
analysis, the study must have obtained each patient’s consent to participate in the trial. 
Observational and retrospective studies often rely on a patient providing consent to have their 
data collected with the purpose of it being used in any studies the researcher deems necessary. 
Because there are no planned interventions in this case, there is rarely any exclusion criteria for 
the study, so all patients are approached for inclusion.  
The CIBMTR patient population was determined using only allogeneic HSCT recipients 
who were transplanted in the United States. Therefore, both single-center and multi-center trials 
were included in this step of the analysis; however, studies with international centers were not. 
Clinical trials in the literature search could be randomized, blinded, or placebo-controlled, 
though no specific study designs were required. If the intervention was a drug, it could be in any 
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phase of development. For studies involving both autologous and allogeneic HSCT recipients, 
only the allogeneic patients were considered for analysis.  
The most important criteria used to determine whether a clinical study could be involved 
in the analysis for this thesis was whether or not the publication included the demographic 
information for its participants. If race was not at least partially reported, the article was 
discounted from the analysis. If just one group was reported (i.e., white: 90%, etc.), then the 
remaining patients were classified as “unknown.” Race information was recorded as detailed as 
possible but was then simplified in order to report the most accurate data, as not all publications 
reported information that corresponded to the same CIBMTR race categories. The simplified 
categories were White, Non-White, and Unknown. 
Google Scholar was instrumental in searching for publications that fulfilled all of these 
criteria. Publications were reviewed from scientific journals such as, but not limited to, New 
England Journal of Medicine, Blood, Cancer, Biology of Blood and Marrow Transplantation, 
and Bone Marrow Transplantation. For two HSCT-specific journals—Biology of Blood and 
Marrow Transplantation and Bone Marrow Transplantation—each monthly issue from 2011–
2015 was examined.  
Once a possible study was identified, the results contained in the publication were 
reviewed by this researcher to determine its eligibility. If an article was deemed eligible for 
inclusion, information about the publication was recorded into a Microsoft Excel database. 
Among the data collected was the intervention of the study, how many centers were involved, 
and the demographics of the patients in the trial. A copy of each article was then saved in a PDF 
format to allow for revisiting in the future.   
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Statistical Analysis 
Statistical analyses were done to determine whether recently published HSCT clinical 
trials demonstrated a reasonable degree of diversity with respect to the total population of 
allogeneic transplant recipients. Analyses utilized data collected in the Microsoft Excel database 
of publication information. Calculations themselves were also done with the help of functions in 
Microsoft Excel. The proportion of minorities in the study (publication) population was 
compared to the proportion of the same minority in the CIBMTR population using a two-
proportion z-test (Jekel et al., 2007). Statistical significance was determined using the P value 
calculated from the z-test. If the P value was less than 0.05, the result was considered to be 
statistically significant.  
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Results 
Combining information from the CIBMTR and HRSA, a five-year allogeneic transplant 
recipient population of 37,768 was identified. A total of 46 clinical studies were identified from 
publications that fulfilled the criteria to be included in the race analysis, 44 of which also had 
corresponding gender data. The articles reported results from both single-center (n=19) and 
multi-center (n=27) trials. This mix of large and small trials led to a total of 4,780 patients that 
were included in the study population.  
Race 
 The CIBMTR allows for patient race information to be collected into five categories: (1) 
American Indian/Alaska Native, (2) Asian, (3) Black or African American, (4) Native Hawaiian 
or Pacific Islander, and (5) White. This does not account for people of mixed race, those who 
chose to consider themselves to be only of Hispanic descent, and those who chose not to report 
their race. If a patient reported their heritage in one of these or another non-categorized fashion, 
they were reported by the CIBMTR in a sixth group: Data Not Available. Authors of published 
clinical trial manuscripts, however, may report their patients’ diversity in any way they choose as 
it is optional for them to report racial characteristics at all. Due to the highly specific criteria 
needed in order to be included for analysis in this thesis, only a small number of articles were 
identified which had any sort of racial information. 
With the CIBMTR reporting specific race categories and study authors reporting very 
little information, it was necessary to simplify and standardize the data between the two groups 
so they could be analyzed for comparison. The detailed CIBMTR information can be found in 
Tables 1 and 2. Data for the study population can be found in Tables 4 and 5 in Appendix B. The 
Data Not Available and Unknown race patients (n=945 for CIBMTR population and n=219 for 
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study population) were discounted from analysis because there was no way to tell what their race 
was or why they were unreported. This left a total of 36,823 and 4,564 thesis participants for the 
CIBMTR and study populations, respectively. Non-white minority patients accounted for 13.3% 
(n=5,003) of the remaining CIBMTR population and 10.3% (n=472) of the study population. 
The differences in those proportions was found to be statistically significant (p<0.000001). 
 
Table 1  
Detailed Race Information for Allogeneic Transplant Recipients Reported to the Center for 
International Blood and Marrow Transplant Research 
Race 2009 2010 2011 2012 2013 Total % 
American Indian or Alaska Native 40 31 32 35 57 195 0.5 Asian 271 287 323 321 364 1,566 4.2 Black or African American 573 559 610 635 726 3,103 8.2 Native Hawaiian or Pacific Islander 28 25 32 22 32 139 0.4 White 5,876 6,072 6,390 6,599 6,883 31,820 84.3 Data Not Available 142 134 188 195 286 945 2.5 
Note: Data was unavailable for those recipients who declined to share information regarding their race or for those 
whose racial information did not fit into one of the five major categories.  
 
Table 2  
Simplified Race Information for Allogeneic Transplant Recipients Reported to the Center for 
International Blood and Marrow Transplant Research 
Race 2009 2010 2011 2012 2013 Total % 
Non-White 912 902 997 1,013 1,179 5,003 13.3 White 5,876 6,072 6,390 6,599 6,883 31,820 84.3 Unknown/Other 142 134 188 195 286 945 2.5 
Note: Race categories were simplified for statistical analysis.  
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Gender 
  Since there were only two categories (men and women) for gender reporting from both 
the CIBMTR and study populations, it allowed for a simpler analysis. Detailed gender 
information for the CIBMTR population can be found in Table 3 and the information for the 
study population can be found in Table 6 in Appendix B. All patients included in the analysis 
had a gender association, with no one being categorized as Unknown. There were 44 studies that 
provided gender information, with a total of 4,755 patients (n=37,768 for CIBMTR population). 
Higher numbers were reported for men in both populations, where they accounted for 58.5% 
(n=22,079) of the CIBMTR population and 55.6% (n=2,644) of the study population; women 
made up only 41.5% and 44.4% (n=15,689; n=2,111), respectively. These proportions showed 
statistical significance (p<0.006).  
 
Table 3  
Gender Information for Allogeneic Transplant Recipients Reported to the Center for 
International Blood and Marrow Transplant Research  
Gender 2009 2010 2011 2012 2013 Total % Men 4,029 4,117 4,417 4,574 4,942 22,079 58.5 Women 2,901 2,991 3,158 3,233 3,406 15,689 41.5  
 
Limitations 
This thesis hoped to include analysis of the differences in age between the CIBMTR and 
study populations. However, this proved to be difficult to analyze due to non-standardized 
reporting practices. The CIBMTR categorizes patients by decade (i.e., 0–10 years, 11–20 years, 
etc.), whereas most publications will report, at most, the age range and median age of the clinical 
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trial’s cohort. Also, the current policy in the United States is to conduct clinical research in 
children only when necessary and only after safety and efficacy have been proven in adults. This 
means clinical trials will often focus on either children (under the age of 18) or adults, rarely 
both in the same study. Also worth noting is the fact that disorders requiring HSCT may differ 
between children and adults. With all of these issues in mind, it was unfeasible to examine age 
differences more closely. 
Due to the reliance on data from outside sources, this investigation was limited in the 
scope of analyses it could perform. For instance, there was no way to identify both the race and 
gender for individual patients. As such, it was not feasible to analyze multi-dimensional 
information (i.e., how many non-white women were in a population). Also limiting the 
investigation was the small number of publications that reported race information. This resulted 
in a small sample size of studies eligible for inclusion. A larger sample size is desired in order to 
ensure a better reflection of clinical trial participants.  
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Discussion 
 While there has been progress for equal inclusion of women and minority patients into 
clinical trials over the last few decades, it seems there is still work to be done in both the 
allogeneic transplant realm and clinical research as a whole.  
Women in Clinical Research 
  The data from this investigation demonstrates that the proportion of women in the study 
population is different from the proportion of women in the CIBMTR population; however, that 
is not an unfavorable result. The results indicate that a larger proportion of women are 
participating in clinical trials than is necessary to appropriately reflect the allogeneic HSCT 
population (44.4% for the study population vs. 41% for the CIBMTR population). Unfortunately, 
this is not the case in many other clinical research specialties. For instance, in 2013, 
Kwiatkowski, Coe, Bailar and Swanson examined how the number of women in cancer-related 
clinical trials had changed since 1990. They found that “the actual inclusion of women 
remain[ed] low, making up only 40.2% of participants in cancer treatment trials and 26.5% of 
participants in cancer prevention trials (excluding sex-specific trials)” (Kwiatkowski et al., 2013, 
p. 2961). This is especially relevant to allogeneic HSCT recipients because the large majority of 
these transplants are performed in patients with hematologic malignancies. So, while data from 
this thesis demonstrated an appropriate representation of women in allogeneic transplant trials, it 
is not indicative of a similar trend in clinical research as a whole.  
 Although the proportion of women in the study population appeared to accurately reflect 
the CIBMTR population, this investigation was limited with regard to any further analysis. 
Because the CIBMTR and HRSA only provided information about broad demographic 
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categories, it was impossible to tell the characteristics of individual patients. Similarly, the 
investigation encountered the same disadvantage with the study population due to authors’ 
apathetic attitude towards reporting demographic details. If those details had been accessible, it 
would have been valuable to perform multi-dimensional analyses to investigate the proportions 
of non-white women in both populations.  
Minorities in Clinical Research 
 The results from this investigation demonstrate that while the number of non-white 
minorities who received allogeneic transplants between 2009 and 2013 was relatively low 
(13.6%), the number of non-white minorities who participated in clinical research was even 
lower (9.9%). This is particularly worrisome as non-white minorities often face riskier transplant 
courses and would most likely benefit from new therapies to help prevent, mitigate, or treat the 
effects of post-HSCT complications.  
Unfortunately, the lower proportion of non-white minorities participating in clinical trials 
was unsurprising as similar trends persist in other subspecialties of clinical research. For 
instance, in their investigation into strictly cancer-related trials, Kwiatkowski et al. (2013) found  
“whites still make up the significant majority (>80% of all participants in cancer clinical trials)” 
(p. 2961).  They also determined that the “number of African Americans participating in cancer 
treatment trials actually declined over the previous 10 years, while there were slight increases in 
the inclusion of other minority groups. Within cancer prevention studies, African Americans 
represented 11.6% of all participants, with other minorities representing ≤4%” (Kwiatkowski et 
el., 2013, p. 2961). These numbers are frighteningly low and the fact that African American 
participation had declined over the previous decade was alarming. With such low minority 
participation numbers, it is difficult for clinical trials to gather enough information about how the 
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non-white population may be affected by new therapies. It is challenging to produce accurate 
safety and efficacy data for new therapies for a diverse population when they are only tested in a 
primarily white population. This could potentially lead to drugs that are dangerous or ineffective 
in the minority population even though they are proven to be safe and effective in the white 
population. It also suggests a barrier to investigational therapies that may have potential 
immediate direct benefit to minority populations.  
 There are several factors that may have contributed to a small number of minorities 
enrolling in clinical trials for allogeneic transplant recipients. First, it has been shown that the 
post-transplant survival of non-white minorities is lower than that of white patients (Hamilton et 
al., 2015). Therefore, the lower number of minority clinical trial participants may be related to 
the fact that those patients just aren’t living long enough to enroll in studies. This is most likely 
due to a higher prevalence of post-transplant complications in the non-white population. 
However, this sort of “time bias” would not explain those clinical trials that are offered to 
potential participants at the time of their HSCT.  
Another possible influence may be socioeconomic factors. For a typical allogeneic 
transplant course, the average medical costs for the first 100 days post-HSCT are approximately 
$200,000 (Majhail et al., 2013). This is obviously a large undertaking for anyone to deal with but 
the out-of-pocket burden is lessened substantially for those patients with good health insurance 
coverage. Patients are forced to take a lot of time off from work and some even lose their jobs 
entirely. With medical bills piling up, some patients may decline to participate in clinical trials 
because they can’t afford to take any more time away from work.  
Yet another possible explanation for the low number of minority patients in HSCT 
clinical trials relates to access to quality medical care. Transplant centers are usually found in 
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densely populated cities where there exists a large pool of potential patients. If non-white 
patients live in more rural areas, they will have to endure long journeys just to travel to the 
transplant center to receive routine care. If a clinical trial requires many study-related visits, 
geographic proximity will certainly play a role in patients’ decision to enroll in the trial; it may 
even prevent the researchers from approaching the patient for possible enrollment.  
It is also worth noting that there is a perception among minority patients, particularly 
African Americans, that “research is biased to benefit white people, resulting in a lack of trust” 
(Smith et al., 2007, p. 425). This is a major barrier to clinical research participation and it’s a 
perception that exists on both on an individual and community level. While this is likely 
multifactorial, possible explanations could be lack of individual and community-wide education 
related to clinical research, as well as lingering effects of the highly unethical Tuskegee Syphilis 
Study performed in African American men under the guidance of the United States Public Health 
Service (Emanuel et al., 2011).  
Future Directions 
 The data from this investigation demonstrated that there is still work to be done to 
increase the number of minority patients enrolling in clinical trials related to allogeneic 
transplants. And, while the numbers in this study indicated an appropriate number of women 
participants, it is important not to lose momentum. In order to maintain this progress, Mazure 
and Jones (2015) suggested that “the NIH should offer priority to grant applications addressing 
sex and gender differences, and the FDA should require sex-specific data for all drug and device 
applications”. They went on to hold all clinical researchers accountable for creating a culture to 
value men and women participants equally. The research community must implement changes, 
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some of which include “requiring that medical and continuing medical education incorporates 
consideration of the influence of sex and gender on health” (Mazure & Jones, 2015).  
Efforts should also be undertaken to recruit more minority patients into clinical trials. 
There were strategies identified by Smith et al. (2013) to help recruit and retain minority 
patients. First, community involvement in clinical research would be beneficial for recruiting and 
education efforts. Such involvement could emphasize the benefits of research and would go a 
long way toward building trust in medical establishments. Next, the clinical trial’s study team 
should have at least some minority representation to aid in building relationships with minority 
patients. Lastly, compensation or other incentives are highly desirable, so offer those whenever 
possible. This would help offset costs incurred during the life of the trial and would demonstrate 
to patients that their participation is valued (Smith et al., 2013).  
 Once researchers have completed their clinical trials and look to publish their results, it is 
imperative that they include the demographics of their participants. There is no other way to 
measure overall progress with regard to the inclusion of women and minorities in clinical 
research other than reviewing the literature. Demographic information is also necessary for 
physicians to know if a study drug in a publication can be safely prescribed to their patients. 
Clinical researchers must be diligent in reporting this information.  
 Finally, more work should be done in examining the representation of women and 
minorities in clinical trials, particularly in subspecialties like allogeneic transplantation. Clinical 
research is meant to advance scientific knowledge in order to help patients and society in the 
future. The only way to accomplish that goal is to perform studies in a diverse patient group 
which mirrors the makeup of society as a whole. The only means to determine where the 
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research community is failing to meet that need is to identify where the deficiencies are and 
dedicate efforts to ensure they are corrected.   
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Conclusions 
 For the last few decades, much progress has been made for the inclusion of women and 
minority patients into clinical trials throughout the United States. This thesis set out to 
investigate the current representation of women and minorities in clinical trials that involved 
allogeneic transplant recipients in order to determine if their inclusion accurately reflected the 
transplant community as a whole. The findings concluded that while the proportion of women 
enrolled in clinical trials was better than anticipated, the number of minority participants 
remained low. This is worrisome because a lack of diversity within clinical trials will lead to a 
shortage of safety and efficacy data for novel therapies in minorities.  
 Though this thesis focused a critical eye on the allogeneic transplant recipient 
community, it is not the only specialty area to face these challenges. Now that the diversity 
deficiencies have been identified, the entire scientific community must continue to implement 
changes that promote the inclusion of women and minorities into clinical trials. This could mean 
differences in funding allocations, publication practices, or recruitment strategies; all of which 
could help the enrollment numbers of underrepresented populations throughout the United 
States. Clinical researchers throughout the country must continue to strive for greater inclusion 
of women and minorities in order to give them access to potentially life-saving therapies and to 
gain more insight into the safety and efficacy of new therapies in these populations.   
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Appendix A: Glossary 
Allogeneic transplant: type of stem cell transplant that involves volunteers donating stem cells  
to recipients in need. 
Autologous transplant: type of stem cell transplant in which a recipient receives their own stem  
cells.  
CIBMTR: Center for International Blood and Marrow Transplant Research. Registry  
responsible for collecting data about stem cell transplants and recipients.  
HSCT: hematopoietic stem cell transplant. See “Autologous transplant” and “Allogeneic  
transplant” for different types of HSCT. 
HLA: human leukocyte antigen. Molecules on the surface of human cells that help the body  
identify other cells that belong there.  
HRSA: Human Resources and Services Administration. An agency of the United States’  
Department of Health and Human Services responsible for reporting and tracking  
outcomes of stem cell transplants nationally.  
NMDP: National Marrow Donor Program. An organization in the United States that maintains a  
registry of volunteers who are willing to act as stem cell donors for patients in need.  
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Appendix B: Tables 
Table 4  
Detailed Race Information from Literature Review Publications 
Author, Year Total  White % B/AA % Asian % AI/AN % NH/PI % O/U % Amin, 2014 126 120 95.2 0 0.0 0 0.0 0 0.0 0 0.0 6 4.8 Anderlini, 2015 79 64 81.0 5 6.3 3 3.8 0 0.0 0 0.0 7 8.9 Baird, 2015 20 18 90.0 1 5.0 0 0.0 0 0.0 0 0.0 0 0.0 Ballen, 2012 13 10 76.9 0 0.0 1 7.7 0 0.0 0 0.0 2 15.4 Bashey, 2011 80 73 91.3 3 3.8 2 2.5 0 0.0 0 0.0 0 0.0 Besien, 2016 97 59 60.8 23 23.7 0 0.0 0 0.0 0 0.0 15 15.5 Devine, 2011 44 42 95.5 0 0.0 0 0.0 0 0.0 0 0.0 2 4.5 El-Jawahri, 2014 
522 470 90.0 13 2.5 22 4.2 0 0.0 0 0.0 17 3.3 
Fathi, 2016 30 27 90.0 0 0.0 0 0.0 0 0.0 0 0.0 3 10.0 Foster, 2012 164 143 87.2 16 9.8 0 0.0 0 0.0 0 0.0 5 3.0 Garcia, 2012 64 53 82.8 4 6.3 0 0.0 0 0.0 0 0.0 2 3.1 Gatza, 2014 34 30 88.2 0 0.0 0 0.0 0 0.0 0 0.0 4 11.8 Grosso, 2015 28 20 71.4 4 14.3 1 3.6 0 0.0 0 0.0 0 0.0 Halasa, 2016 44 44 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 Jim, 2013 24 23 95.8 0 0.0 0 0.0 0 0.0 0 0.0 1 4.2 
Kamani, 2012 8 0 0.0 7 87.5 0 0.0 0 0.0 0 0.0 1 12.5 Karras, 2013 65 53 81.5 0 0.0 0 0.0 0 0.0 0 0.0 12 18.5 Khera, 2014 268 246 91.8 0 0.0 0 0.0 0 0.0 0 0.0 13 4.9 Kimball, 2016 184 165 89.7 1 0.5 7 3.8 1 0.5 0 0.0 8 4.3 Ladas, 2015 30 16 53.3 12 40.0 2 6.7 0 0.0 0 0.0 0 0.0 Leen, 2013 50 38 76.0 7 14.0 0 0.0 0 0.0 0 0.0 5 10.0 Leung, 2011 190 139 73.2 0 0.0 0 0.0 0 0.0 0 0.0 51 26.8 Liesveld, 2013 19 17 89.5 1 5.3 0 0.0 0 0.0 0 0.0 0 0.0 
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Table 4 (continued) 
Author, Year Total  White % B/AA % Asian % AI/AN % NH/PI % O/U % Liu, 2011 45 32 71.1 9 20.0 0 0.0 0 0.0 0 0.0 4 8.9 
Loggers, 2014 18 18 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 Mahadeo, 2015 22 3 13.6 5 22.7 3 13.6 0 0.0 0 0.0 2 9.1 Majhail, 2012 25 24 96.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 Marty, 2013 230 207 90.0 0 0.0 0 0.0 0 0.0 0 0.0 23 10.0 Muffly, 2013 166 154 92.8 8 4.8 0 0.0 0 0.0 0 0.0 4 2.4 Oberg, 2012 80 25 31.3 16 20.0 5 6.3 0 0.0 0 0.0 34 42.5 Pasquini, 2016 1013 896 88.5 54 5.3 29 2.9 5 0.5 5 0.5 24 2.4 Pidala, 2015 12 12 100.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 Shea, 2011 44 32 72.7 0 0.0 0 0.0 0 0.0 0 0.0 12 27.3 
Shook, 2015 8 4 50.0 2 25.0 0 0.0 0 0.0 0 0.0 1 12.5 Simmons, 2011 26 18 69.2 0 0.0 0 0.0 0 0.0 0 0.0 8 30.8 Stieglitz, 2014 85 67 78.8 3 3.5 7 8.2 0 0.0 0 0.0 8 9.4 Syrjala, 2011 92 87 94.6 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 Thakar, 2011 6 4 66.7 1 16.7 0 0.0 0 0.0 0 0.0 0 0.0 Triplett, 2015 17 7 41.2 3 17.6 0 0.0 0 0.0 0 0.0 7 41.2 Wallace, 2015 134 116 86.6 0 0.0 0 0.0 0 0.0 0 0.0 18 13.4 Weisdorf, 2012 24 15 62.5 6 25.0 1 4.2 0 0.0 0 0.0 2 8.3 Williams, 2014 166 152 91.6 8 4.8 3 1.8 0 0.0 0 0.0 0 0.0 Windreich, 2016 19 15 78.9 1 5.3 2 10.5 0 0.0 0 0.0 1 5.3 Wood, 2013 22 18 81.8 2 9.1 1 4.5 0 0.0 0 0.0 0 0.0 Wood, 2016 310 284 91.6 10 3.2 5 1.6 1 0.3 3 1.0 7 2.3 Zhang, 2016 33 29 87.9 2 6.1 2 6.1 0 0.0 0 0.0 0 0.0 Totals 4,780 4,089 85.5 227 4.7 96 2.0 7 0.1 8 0.2 306 6.4 
Note: This table includes detailed race information gathered from articles in scientific journals that were identified 
during a review of recent literature. Only allogeneic transplant recipients were included. If race reporting was 
incomplete in an article, patients were reported as Other/Unknown. Race abbreviations: AI/NA: American Indian or 
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Native Alaskan; B/AA: Black or African American; NH/PI: Native Hawaiian or Pacific Islander; O/U: 
Other/Unknown.   
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Table 5  
Simplified Race Information from Literature Review Publications  
Author, Year Total White % NW % Unk % 
Amin, 2014 126 120 95.2 0 0.0 6 4.8 Anderlini, 2015 79 64 81.0 8 10.1 7 8.9 
Baird, 2015 20 18 90.0 2 10.0 0 0.0 
Ballen, 2012 13 10 76.9 1 7.7 2 15.4 
Bashey, 2011 80 73 91.3 7 8.8 0 0.0 
Besien, 2016 97 59 60.8 23 23.7 15 15.5 
Devine, 2011 44 42 95.5 0 0.0 2 4.5 
El-Jawahri, 2014 522 470 90.0 35 6.7 17 3.3 
Fathi, 2016 30 27 90.0 0 0.0 3 10.0 
Foster, 2012 164 143 87.2 16 9.8 5 3.0 
Garcia, 2012 64 53 82.8 9 14.1 2 3.1 
Gatza, 2014 34 30 88.2 0 0.0 4 11.8 
Grosso, 2015 28 20 71.4 8 28.6 0 0.0 
Halasa, 2016 44 44 100.0 0 0.0 0 0.0 
Jim, 2013 24 23 95.8 0 0.0 1 4.2 
Kamani, 2012 8 0 0.0 8 100.0 0 0.0 
Karras, 2013 65 53 81.5 0 0.0 12 18.5 
Khera, 2014 268 246 91.8 20 7.5 2 0.7 
Kimball, 2016 184 165 89.7 14 7.6 10 5.4 
Ladas, 2015 30 16 53.3 14 46.7 0 0.0 
Leen, 2013 50 38 76.0 7 14.0 5 10.0 
Leung, 2011 190 139 73.2 51 26.8 0 0.0 
Liesveld, 2013 19 17 89.5 2 10.5 0 0.0 
Liu, 2011 45 32 71.1 9 20.0 4 8.9 
Loggers, 2014 18 18 100.0 0 0.0 0 0.0 
Mahadeo, 2015 22 3 13.6 18 81.8 1 4.5 
Majhail, 2012 25 24 96.0 1 4.0 0 0.0 
Marty, 2013 230 207 90.0 0 0 23 10.0 
Muffly, 2013 166 154 92.8 8 4.8 4 2.4 
Oberg, 2012 80 25 31.3 21 26.3 34 42.5 
Pasquini, 2016 1013 896 88.5 93 9.2 24 2.4 
Pidala, 2015 12 12 100.0 0 0.0 0 0.0 
Shea, 2011 44 32 72.7 0 0.0 12 27.3 
Shook, 2015 8 4 50.0 3 37.5 1 12.5 
Simmons, 2011 26 18 69.2 0 0.0 8 30.8 
Stieglitz, 2014 85 67 78.8 10 11.8 8 9.4 
Syrjala, 2011 92 87 94.6 5 5.4 0 0.0 
Thakar, 2011 6 4 66.7 2 33.3 0 0.0 
Triplett, 2015 17 7 41.2 10 58.8 0 0.0 
Wallace, 2015 134 116 86.6 18 13.4 0 0.0 
Weisdorf, 2012 24 15 62.5 9 37.5 0 0.0 
Williams, 2014 166 152 91.6 14 8.4 0 0.0 
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Table 5 (continued) 
 
Note: In order to simplify representation calculations, this table reclassified the detailed race information found in 
articles from the literature review. Calculations were done based on White/Non-White/Unknown categories, with the 
patients of unknown race discounted from the analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author, Year Total White % NW % Unk % 
Windreich, 2016 19 15 78.9 4 21.1 0 0.0 Wood, 2013 22 18 81.8 4 18.2 0 0.0 
Wood, 2016 310 284 91.6 19 6.1 7 2.3 
Zhang, 2016 33 29 87.9 4 12.1 0 0.0 
Totals 4,780 4,089 85.5 472 9.9 219 4.6 
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Table 6  
Gender Information from Literature Review Publications 
Author, Year Total Patients Men % Women % Amin, 2014 126 86 68.3 40 31.7 Anderlini, 2015 79 40 50.6 39 49.4 Baird, 2015 20 14 70.0 6 30.0 Bashey, 2011 80 49 61.3 31 38.8 Besien, 2016 97 60 61.9 37 38.1 Devine, 2011 44 16 36.4 28 63.6 El-Jawahri, 2014 522 297 56.9 225 43.1 Fathi, 2016 30 18 60.0 12 40.0 Foster, 2012 164 81 49.4 83 50.6 Garcia, 2012 64 42 65.6 22 34.4 Gatza, 2014 34 26 76.5 8 23.5 Grosso, 2015 28 19 67.9 9 32.1 Halasa, 2016 44 27 61.4 17 38.6 Jim, 2013 24 12 50.0 12 50.0 Kamani, 2012 8 2 25.0 6 75.0 Karras, 2013 65 39 60.0 26 40.0 Khera, 2014 268 136 50.7 132 49.3 Kimball, 2016 184 104 56.5 80 43.5 Ladas, 2015 30 16 53.3 14 46.7 Leen, 2013 50 33 66.0 17 34.0 Leung, 2011 190 114 60.0 76 40.0 Liesveld, 2013 19 7 36.8 12 63.2 Liu, 2011 45 30 66.7 15 33.3 Loggers, 2014 18 8 44.4 10 55.6 Mahadeo, 2015 22 7 31.8 15 68.2 Majhail, 2012 25 13 52.0 12 48.0 Marty, 2013 230 132 57.4 98 42.6 Muffly, 2013 166 108 65.1 58 34.9 Oberg, 2012 80 51 63.8 29 36.3 Pasquini, 2016 1,013 503 49.7 510 50.3 Shea, 2011 44 35 79.5 9 20.5 Shook, 2015 8 5 62.5 3 37.5 Simmons, 2011 26 16 61.5 10 38.5 Stieglitz, 2014 85 56 65.9 31 36.5 Syrjala, 2011 92 43 46.7 49 53.3 Thakar, 2011 6 4 66.7 2 33.3 Triplett, 2015 17 11 64.7 6 35.3 Wallace, 2015 134 87 64.9 47 35.1 Weisdorf, 2012 24 11 45.8 13 54.2 Williams, 2014 166 76 45.8 90 54.2 Windreich, 2016 19 9 47.4 10 52.6 Wood, 2013 22 11 50.0 11 50.0 Wood, 2016 310 173 55.8 137 44.2 Zhang, 2016 33 19 57.6 14 42.4 Totals 4,755 2,644 55.6 2,111 44.4 
Note: This table includes gender information gathered from articles in scientific journals that were identified during 
a review of recent literature.  
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Appendix C: Human Subjects Exemption Letter 
 
